Literature DB >> 2161396

Increased densities of peripheral-type benzodiazepine receptors in brain autopsy samples from cirrhotic patients with hepatic encephalopathy.

J Lavoie1, G P Layrargues, R F Butterworth.   

Abstract

Peripheral-type benzodiazepine receptors were evaluated using the specific ligand [3H]-PK 11195 in brain homogenates from nine cirrhotic patients who died in hepatic coma and from an equal number of age-matched control subjects. Histopathological studies showed evidence of severe Alzheimer type II astrocytosis in the brains of all cirrhotic patients. Saturation-binding assays revealed a single saturable binding site for [3H]-PK 11195 in brain, with affinities in the 2- to 3-nmol/L range. Diazepam was found to be a relatively potent inhibitor of 3H-PK 11195 binding (IC50 = 253 nmol/L), whereas the central benzodiazepine antagonist Ro 15-1788 displaced 3H-PK 11195 binding with low affinity (IC50 greater than 40 mumols/L). Densities of [3H]-PK 11195 binding sites were found to be increased by 48% (p less than 0.01) and 25% (p less than 0.05) in frontal cortex and caudate nuclei, respectively, from cirrhotic patients. Densities of [3H]-PK 11195 binding sites in frontal cortex from two nonencephalopathic cirrhotic patients were not significantly different from control values. No concomitant changes of affinities of these binding sites were observed. Because it has been suggested that peripheral-type benzodiazepine receptors may be localized on mitochondrial membranes and may therefore be involved in cerebral oxidative metabolism, the alterations observed in this study could be of pathophysiological significance in hepatic encephalopathy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2161396     DOI: 10.1002/hep.1840110524

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  36 in total

Review 1.  Alterations of neurotransmitter-related gene expression in human and experimental portal-systemic encephalopathy.

Authors:  R F Butterworth
Journal:  Metab Brain Dis       Date:  1998-12       Impact factor: 3.584

Review 2.  Neurotransmitter dysfunction in hepatic encephalopathy: new approaches and new findings.

Authors:  R F Butterworth
Journal:  Metab Brain Dis       Date:  2001-06       Impact factor: 3.584

Review 3.  Pathogenesis and treatment of portal-systemic encephalopathy: an update.

Authors:  R F Butterworth
Journal:  Dig Dis Sci       Date:  1992-03       Impact factor: 3.199

Review 4.  Pathogenesis of hepatic encephalopathy in cirrhosis: the concept of synergism revisited.

Authors:  Roger F Butterworth
Journal:  Metab Brain Dis       Date:  2015-11-02       Impact factor: 3.584

5.  Concentration, distribution, and influence of aging on the 18 kDa translocator protein in human brain: Implications for brain imaging studies.

Authors:  Junchao Tong; Belinda Williams; Pablo M Rusjan; Romina Mizrahi; Jean-Jacques Lacapère; Tina McCluskey; Yoshiaki Furukawa; Mark Guttman; Lee-Cyn Ang; Isabelle Boileau; Jeffrey H Meyer; Stephen J Kish
Journal:  J Cereb Blood Flow Metab       Date:  2019-06-20       Impact factor: 6.200

6.  Cerebrospinal fluid amino acids in relation to neurological status in experimental portal-systemic encephalopathy.

Authors:  G Therrien; R F Butterworth
Journal:  Metab Brain Dis       Date:  1991-06       Impact factor: 3.584

7.  Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain.

Authors:  M Cosenza-Nashat; M-L Zhao; H-S Suh; J Morgan; R Natividad; S Morgello; S C Lee
Journal:  Neuropathol Appl Neurobiol       Date:  2008-12-11       Impact factor: 8.090

8.  Benzodiazepine binding sites in alcoholic cirrhotics: evidence for gender differences.

Authors:  P R Dodd
Journal:  Metab Brain Dis       Date:  1995-03       Impact factor: 3.584

9.  Persistent region-dependent neuroinflammation, NMDA receptor loss and atrophy in an animal model of penetrating brain injury.

Authors:  Rachel Grossman; Charles M Paden; Pamela A Fry; Ryon Sun Rhodes; Anat Biegon
Journal:  Future Neurol       Date:  2012-05-01

Review 10.  The neurosteroid system: an emerging therapeutic target for hepatic encephalopathy.

Authors:  Samir Ahboucha; Roger F Butterworth
Journal:  Metab Brain Dis       Date:  2007-12       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.